Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antiviral Treatment Clear all
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Not applicable Interventional

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

NCT00002155
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 1Phase 2 Interventional

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

NCT00120835
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, pegylated interferon
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Timeline
Started 2004
U.S. locations
2
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Jul 23, 2026, 9:04 PM EDT
Completed No phase listed Observational

Gilead Sustained Virologic Response (SVR) Registry

NCT01457755
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
162
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Jul 23, 2026, 9:04 PM EDT
Terminated Phase 3 Interventional Results available

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

NCT00605384
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir + Tenofovir, Adefovir + continuing Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2010 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

NCT00000712
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
8
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

NCT00005918
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Not applicable Interventional

A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes

NCT00002355
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Fomivirsen sodium
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

NCT00002364
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment

NCT00680342
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Silymarin, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

NCT00002327
View directory record Official record
Conditions
HIV Infections, Condyloma Acuminata
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

NCT05381454
View directory record Official record
Conditions
Respiratory Viral Infection, Antiviral Treatment, COVID-19
Interventions
Mitoquinone/mitoquinol mesylate
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 23, 2026, 9:04 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

NCT06749054
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection

NCT00019240
View directory record Official record
Conditions
Sarcoma
Interventions
cidofovir
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Not applicable Interventional

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

NCT00002001
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

Combination Drug Therapy for Patients With Hepatitis C

NCT00001729
View directory record Official record
Conditions
Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Not applicable Interventional

A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

NCT00001111
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Gamma Interferon Therapy for Chronic Hepatitis C

NCT00028275
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Gamma Interferon 1b
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jul 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

NCT00000628
View directory record Official record
Conditions
HIV Infections
Interventions
L-697,661, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Jul 23, 2026, 9:04 PM EDT